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Background: Universal hepatitis B virus (HBV) vaccination of newborn babies was introduced in Italy in 1991 and
was extended to 12-years-old children for the first 12 years of application so as to cover in a dozen years the Italian
population aged 0-24 years. The aim of this study was to identify factors associated with long-term immunogenicity
against HBV 17 years after primary vaccination in students attending medical schools in Naples, Italy.
Methods: 1,704 students attending the school of medicine, schools of the healthcare professions, or postgraduate
medical schools of the Second University of Naples, Italy, from September 2012 to December 2013 were enrolled in
this study. Of these, 588 had been vaccinated against HBV in infancy and 1,116 when 12 years old. Multivariate
logistic regression analysis was used to identify factors associated with the level of long-term immunogenicity.
Results: All vaccinated subjects were HBsAg/anti-HBc negative: 270 (15.8%) had an anti-HBs titer between 1 and
9 IU/L, 987 (57.9%) between 10 and 400 IU/L, and 447 (26.3%) over 400 IU/L. When compared with the latter two
subgroups, those with anti-HBs titers lower than 10 IU/L were younger (24 ± 5.2 years vs. 26 ± 4.9 years, p < 0.000),
more frequently students attending a healthcare school (59% vs. 47%, p < 0.001), and more frequently had been
vaccinated in infancy (50% vs. 31.5%, p < 0.0001). Multivariate logistic regression identified age at vaccination as the
only factor independently associated with an anti-HBs titer <10 IU/L (OR: 2.43; C.I. 95%: 1.57–3.76, p = 0.001).
Conclusions: Universal HBV vaccination in Italy has been more effective in generating a prolonged protective
response in subjects vaccinated at adolescence than in infancy. Students with a low anti-HBs titer should be
considered for a booster dose because most will be exposed to the risk of acquiring HBV for decades.
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Infection with hepatitis B virus (HBV) is a leading cause
of acute and chronic liver disease worldwide [1]. The
World Health Organization (WHO) estimates that, glo-
bally, about 2 billion people have been infected with
HBV, more than 350 million are chronically infected,
and nearly one million per year die from its acute or
chronic sequelae, such as fulminant hepatitis, liver cir-
rhosis, and hepatocellular carcinoma [2]. The prevalence* Correspondence: nicola.coppola@unina2.it
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unless otherwise stated.of HBV-related hepatitis varies across countries: in in-
dustrialized West European countries and North America,
the prevalence of HBV surface antigen (HBsAg) positivity
in the general population is less than 2% (low endemicity);
in most countries of the Mediterranean, East Europe, and
Asia it ranges between 2–8% (intermediate endemicity);
whereas it is over 8% in some developing countries in
Far-East Asia and Sub-Saharan Africa (high endemicity) [3,4].
In Italy, the epidemiology of HBV infection has chan-
ged substantially over the last 50 years: there has been a
remarkable, progressive reduction in the incidence of
acute hepatitis B (from 10/100,000 inhabitants in 1984
to 0.85/100,000 in 2012) and in the percentage of HBV-
related cases among patients with chronic hepatitisl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the prevalence of chronic carriers of HBsAg in the gen-
eral population has decreased from nearly 3% in the
1980s to 1% or less in 2010 [5]. The reasons for this may
be due to a number of relevant events occurring in Italy
over the last three decades, including improved socio-
economic conditions; a consistent reduction in the number
of large families, in which HBV is often transmitted among
siblings [7]; the national educational campaigns against
HIV infection; mandatory screening for women during
pregnancy and/or at the time of delivery; and a mass vac-
cination campaign against HBV [8,9].
Universal HBV vaccination of newborn babies was in-
troduced in Italy in 1991 and was extended to 12-year-old
children for the first 12 years of application so as to cover
in a dozen years the Italian population aged 0–24 years.
The schedule involves HBV vaccination doses at months
0, 1, and 6, starting from the third month of life for in-
fants. In Italy, HBV vaccination is also recommended for
people at risk of acquiring HBV infection [10-12].
A debated issue is how long a protective antibody re-
sponse may persist after vaccination. A study performed
in Italy in 2003 showed that after primary vaccination of
infants and adolescents, the antibody response persisted
at levels considered protective (>10 IU/L) for at least
10 years in most subjects [13]. However, data on the per-
sistence of the efficacy of vaccination for longer periods
are scant and fragmentary [14-18].
The present study was therefore carried out to evalu-
ate the long-term immunogenicity and effectiveness of
HBV vaccination and to identify independent predictive
factors of long-term immunogenicity. To this end, stu-
dents attending the medical and healthcare schools of
the Second University of Naples, Italy, were enrolled in
this study.
Methods
From September 2012 to December 2013, we anonym-
ously screened the levels of serum HBsAg, anti-HBs, and
anti-HBc in all students attending the 6th year of the med-
ical school, the 1st year of the health profession schools
(nursing, pediatric nursing, radiology, and midwifery), and
the postgraduate medical schools of the Second University
of Naples, Naples, Italy. The participation rate for this
study was 100%.
A pre-coded questionnaire on demographics, previous
exposure to HBV, and HBV vaccination was filled in by
each student. Out of the total of 1,727 students exam-
ined, 23 had escaped HBV vaccination. The remaining
1,704 had been vaccinated and were enrolled for this
study. Of these, 588 had received a course of 3 pediatric
doses (10 μg) of recombinant hepatitis B vaccine at their
3rd, 5th, and 11th month of postnatal life and were clas-
sified as “vaccinated in infancy” for this paper; 1,116 hadreceived the course of 3 adult doses (20 μg) of the same
vaccine when 12 years old. The information on HBV vac-
cination given by the students was always checked against
their vaccination cards.
HBV serum markers (HBsAg, anti-HBs, and total anti-
HBc) were determined using commercial immunoenzy-
matic assays (Abbott Laboratories, North Chicago, IL,
USA). Anti-HBs titers were measured on a calibration
curve generated with the WHO reference standard, and
are expressed in IU/L. In particular, actual values were ob-
tained for anti-HBs titers between 10 and 400 IU/L, and
for this interval the geometric mean was calculated with
standard procedures; however, for values found <10 IU/L
or >400 IU/L, the laboratory readout indicated only
“under 10 IU/L” or “over 400 IU/L”, respectively.
The efficacy of anti-HBV vaccination in our cohort
was calculated with Orenstain’s equation [19]: VE (%) =
[(ARU - ARV)/ARU] x 100, where VE is vaccine efficacy
(the per cent reduction in disease incidence attributable to
vaccination), ARU is the attack rate in unvaccinated sub-
jects, and ARV is the attack rate in vaccinated subjects.
All procedures were performed in compliance with the
Declaration of Helsinki, with the current healthcare stan-
dards indicated by the Italian Ministry of Health and in
accordance with the guideline established by the Ethic
Committee of the Azienda Ospedaliera of the Second
University of Naples. The Italian law considers the stu-
dents attending the medical schools as health care workers
since they make their clinical practice in the University
Hospitals and it is mandatory for the Universities to con-
trol the immunological protection of both health care
workers and students against infectious agents like HBV.
This is established by the Legislative Decree n. 81, article
279 of the Italian Republic, April 9, 2008. Thus, an ap-
proval of an Ethic Committee is not required, but, accord-
ing to the Italian law for retrospective studies, only a
communication, that was done, is required. Moreover, in
full agreement with the rationale and the aim of the
study, all students signed a written informed consent
form. The sera were tested blindly, and all personal infor-
mation regarding the students were protected according
to Italian law.
Statistical analysis was performed with StatGraph, ver-
sion 3.0. Continuous variables are given as mean ±
standard deviation, and categorical variables as the abso-
lute value and relative frequency. Differences in means
were evaluated with unpaired Student t-test, and the
chi-squared test was applied to categorical variables. A
p-value <0.05 was considered to be statistically signifi-
cant. Odds ratio (OR), with a 95% confidence interval
(CI), was estimated by a logistic regression model to
evaluate the confounding between the variation of anti-
HBs titers <10 IU/L with sex, age at vaccination, years
from vaccination, and the type of school attended as
Table 1 Demographics of the vaccinated, HBsAg-negative
students enrolled
Characteristic Value
N° of subjects 1,704
Age, years 26 ± 4.7
Females 1,033 (60.6)
Years since vaccination 17.7 ± 3.9
Place of birth: Italy 1,685 (98.9)
Elsewhere 19 (1.1)
Attending: School of medicine 525 (30.8)
Healthcare profession school 829 (48.6)
Postgraduate medical school 350 (20.6)
Vaccination conducted: in infancy 588 (34.6)
at 12 years old 1116 (65.4)







HBsAb titer: <10 IU/L 270 (15.8)
10–400 IU/L 987 (57.9)
447 (26.3)>400 IU/L
Continuous variables are given as mean ± SD; categorical variables are given
as n° (%).
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cally significant.
Results
Of the 23 students who had escaped HBV vaccination,
22 were HBsAg/anti-HBs/anti-HBc negative, and one was
HBsAg positive. All vaccinated students were HBsAg/
anti-HBc negative (Figure 1). The efficacy of anti-HBV
vaccination was thus 100%.
The demographic and epidemiologic characteristics of
the 1,704 vaccinated students are given in Table 1. One
thousand thirty-three students (60.6%) were female and
1,685 (98.9%) were of a Caucasian Italian ethnic back-
ground. The ages of the 525 students attending the school
of medicine and the 829 students attending a healthcare
profession school were 26.5 ± 3.7 and 23.8 ± 4.9 years, re-
spectively; the 350 postgraduate medical school students
were older (29.7 ± 2.2 years). The majority (84.2%) of the
students had an anti-HBs titer >10 IU/L: 57.9% between
10 and 400 IU/L and 26.3% over 400 IU/L (Table 1).
Compared with students vaccinated at their 12th year
of age, those vaccinated in infancy were younger (21.5 ±
0.9 vs. 27.9 ± 4.4, p <0.000), more frequently female (72%
vs. 55%, p <0.000), and more frequently attending a
healthcare profession school than either the school of
medicine or a postgraduate medical school (94% vs. 24.7%,
p <0.000) (Table 2). Overall, a longer period of time had
elapsed since their vaccination. Moreover, the group of
students vaccinated in infancy had a significantly higher
prevalence of individuals with a low (<10 IU/L) anti-HBs
titer (23.0 vs. 12.1%), more subjects with an anti-HBs
titer ranging between 10 and 400 IU/L (67.3 vs. 53%),
and a definitely lower rate of subjects with an anti-HBs
titer >400 IU/L (9.7 vs. 34.9%), p <0.000). The geometric
mean of anti-HBs titer (calculated among students with a
level ranging 10–400 IU/L) was higher for the group vac-













Figure 1 Flow chart of the students studied at the Second UniversityTo render the time from vaccination comparable in
the two groups, a separate evaluation was performed on
the sub-group of students vaccinated between 1991 and
1995. This assessment confirmed the above-mentioned
findings: in fact, of the 588 students vaccinated in infancy
during this period, 23% had an anti-HBs titer lower than











of Naples from September 2012 to December 2013.
Table 2 Characteristics of the 1,704 vaccinated students stratified by age at vaccination
Vaccinated in infancy Vaccinated at 12 years old p
N° of students 588 1,116
Age, years 21.5 ± 0.9 27.9 ± 4.4 0.000
Females 421 (72) 613 (55) 0.000
Place of birth: Italy 584 (99.5) 1101 (99) n.s.
Elsewhere 4 (0.5) 15 (1)
Attending: School of medicine 33 (6) 492 (44)
0.000*Healthcare profession school 555 (94) 274 (24.7)
Postgraduate medical school 0 350 (31.3)
Years from vaccination 21.5 ± 0.9 15.6 ± 3.2 0.000
Students with HBsAb < 10 IU/L 135 (23) 135 (12.1) 0.000
Students with HBsAb 10–400 IU/L 396 (67.3) 591 (53) 0.000
Genometric mean, IU/L 30.4 59.6 0.000**
Students with HBsAb >400 IU/L 57 (9.7) 390 (34.9) 0.000
Students with HBsAb <10 IU/L: Female 91/421 (21.6) 67/613 (11) n.s.
Male 44/167 (26.5) 68/503 (13.5)
Vaccinated 1991–1995 135/588 (23) 13/202 (6.4) 0.000
Vaccinated 1996–2002 - 122/914 (13.3) -
*Healthcare profession school students vs. all medical school students (graduate + postgraduate).
**Mann–Whitney Test.
Continuous variables are given as mean ± SD; categorical variables are given as n° (%).
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nated during adolescence in the same period, the preva-
lences were 6.4%, 60.4%, and 33.2%, respectively (p <0.000).
Even for this sub-group, the geometric mean of anti-








at 12 years old








*Healthcare profession school students vs. all medical school students (graduate + p
variables are given as n° (%).was higher in those vaccinated in adolescence (56.5 vs.
30.5 IU/L, p < 0.0001).
The characteristics of the vaccinated students stratified
according to HBsAb titer are given in Table 3. The sub-
jects with an anti-HBs titer <10 IU/L were younger,<10 IU/L ≥10 IU/L P
270 1,434
24 ± 5.18 26 ± 4.86 0.000
158 (58.5) 875 (60) n.s
66 (24.4) 459 (32) 0.0001*
159 (59) 670 (47)
45 (16.6) 305 (21)
135 (50) 452 (31.0) 0.000
135 (50) 982 (67.0)
36 (13.0) 153 (11.0) n.s
92 (34.0) 352 (24.4)
20 (7.0) 136 (9.6)
25 (10.0) 151 (10.5)
26 (10.0) 210 (14.5)
37 (14.0) 267 (18.5)
34 (12.0) 165 (11.5)
18.29 ± 3.97 17.57 ± 3.85 0.005
ostgraduate). Continuous variables are given as mean ± SD; categorical
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and more frequently had been vaccinated in infancy. Fe-
males were prevalent to a similar degree in both groups.
To identify factors independently associated with an
anti-HBs titer <10 IU/L, a logistic regression analysis was
performed with sex, age at vaccination, type of school
attended, and years elapsed from vaccination as the vari-
ables (Table 4). The analysis identified age at vaccination
as the only independent predictor of low anti-HBs titer
(OR: 2.43; C: 95%, 1.57–3.76, p =0.00).
Discussion
Universal vaccination against HBV infection was intro-
duced in Italy in 1991. All newborn babies were vacci-
nated (at month 3, 5, and 11) to prevent the risk of
acquiring HBV infection by perinatal and familial trans-
mission, while all children aged 12 years were vaccinated
to prevent HBV transmission by unsafe sexual activity or
intravenous drug addiction. With this strategy, the Ital-
ian population aged 0–24 was covered by 2003. It has
also allowed us to compare the immunogenicity and effi-
cacy of the HBV vaccine in 588 students vaccinated during
infancy and in 1,116 students vaccinated during adoles-
cence; only 23 students in the cohort escaped the universal
HBV vaccination program, mostly because of socio-
cultural reasons.
HBV vaccination had an excellent efficacy (100%),
since none of the vaccinated students have been infected
with HBV, as reflected by the absence of positivity to
serum HBsAg or anti-HBc after a mean period of nearly
17 years; on the other hand, one (4.3%) of the 23 students
who were not vaccinated acquired an HBV infection and
became a chronic HBsAg carrier. The high immunogen-
icity of HBV vaccination is demonstrated by the ob-
servation that nearly 90% of students vaccinated during
adolescence and three-quarters of those vaccinated at
infancy had an anti-HBs titer ≥10 IU/L, which is con-
ventionally accepted as protective. In addition, students
with an anti-HBs titer <10 IU/L had a detectable antibody
titer ranging 1–9 IU/L. Indeed, there is evidence, con-
firmed also in the present study, that the protection
induced by the recombinant HBV vaccine persists even
when the anti-HBs titer declines below 10 IU/L [20-25].Table 4 Logistic regression analysis of variables related
to variation of anti-HBs titer <10 IU/L
Parameter Odds ratio 95% CI p
Gender: female vs. male 0.77 0.59–1.02 0.07
Age at vaccination: at
infancy vs. adolescence
2.43 1.57–3.76 0.00
Type of school: health
profession vs. all medical
0.96 0.66–1.40 0.83
Years from vaccination 0.99 0.95–1.04 0.83
OR, Odds Ratio.; 95% CI, 95% confidence interval.The immunogenicity was higher in students vaccinated
during adolescence, as shown by the higher prevalence of
students with an anti-HBs titer >400 IU/L, the higher
prevalence of those with anti-HBs titers ranging 10–
400 IU/L, and by the lower prevalence of subjects with an
anti-HBs titer <10 IU/L. Moreover, the geometric mean of
the sub-group of subjects with an anti-HBs titer 10–
400 IU/L was significantly higher in subjects vaccinated at
an the older age. This finding was independent of time
elapsed from vaccination to screening, as shown by the
sub-group of students vaccinated between 1991 and 1995.
Indeed, multivariate analysis identified vaccination at in-
fancy as the only factor associated with a low (<10 IU/L)
anti-HBs titer. Thus, vaccination in adolescence results in
a more effective HBV immunogenicity, most probably
reflecting the progressive improvement of the immune
system during childhood [26]. Indeed, the immune system
in infancy is characterized by impaired T cell function,
lower interaction between B and T cells, restriction of the
immunoglobulin repertoire, and low affinity antibody re-
sponse [26]. These factors, along with the presence of
serum anti-HBs in some mothers [27], might affect the re-
sponse to HBV vaccine in newborn babies and explain the
lower immunogenicity of HBV vaccine when administered
in infancy. These observations should induce healthcare
authorities to reconsider their vaccination strategies in in-
fancy for a more effective response.
As mentioned before, it is common opinion that HBV-
vaccinated subjects with an anti-HBs titer that has de-
creased to below 10 UI/L or that have become anti-HBs
negative are still considered protected against HBV infec-
tion, since the immunological memory to HBsAg may per-
sist even in these cases and ensure a rapid rise of protective
antibodies in the case of an HBV assault [13,18,28]. Stu-
dents attending healthcare profession schools are consid-
ered potentially exposed to hospital infections to a similar
degree as healthcare workers (HCWs) [29] and will prob-
ably be exposed to HBV for decades once they have be-
come active HCWs themselves. Furthermore, it has been
estimated that the incidence of injuries due to sharp ob-
jects in HCWs ranges from 1.4 to 9.5 per 100 HCWs per
year, and that transmission of HBV results in 0.42 HBV in-
fections per 100 sharp-object injuries per year [30,31].
Therefore, a booster dose should be considered for all
subjects with a low anti-HBs titer [32-35].
Conclusions
To the best of our knowledge, the present study is the
first to evaluate the efficacy and immunogenicity of HBV
vaccination in a large series of subjects with a high
chance of being exposed to HBV for decades. HBV vac-
cination has an excellent efficacy – as demonstrated by
the absence of HBsAg and anti-HBc in all vaccinated
students – and high immunogenicity – as indicated by
Coppola et al. BMC Infectious Diseases  (2015) 15:149 Page 6 of 7the high anti-HBs titers found 17 years after vaccination.
However, the effect is stronger when conducted in
adolescence. Worldwide, universal HBV vaccination is
administrated in infancy, but this practice produces lower
immunogenicity than vaccination in adolescence or adult-
hood. Moreover, although immunological memory may
persist for years after HBV vaccination, even in the ab-
sence of anti-HBs, the possibility remains that the im-
mune system of HCWs vaccinated in infancy and
presenting with a low anti-HBs titer may become over-
whelmed by a highly infectious HBV inoculum during a
long professional life. Thus, the administration of a
booster dose of HBV vaccine should be considered for
these individuals.
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